Abstract:Background: Drug-induced liver injury (DILI) is a leading cause of drug development failures during clinical trials and post-market introduction. Current biomarkers, such as ALT and AST, lack the necessary specificity and sensitivity needed for accurate detection. Exosomes, which protect LncRNAs from RNase degradation, could provide reliable and easily accessible options for biomarkers. Materials and methods: RNA-sequencing was used to identify differentially expressed LncRNAs (DE-LncRNAs), followed by isolation of LncRNAs from plasma exosomes in this study. Exosome characterization was conducted by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot (WB). Bioinformatics analysis included functional enrichment and co-expression network analysis. Five rat models were established, and quantitative real-time PCR was used to verify the specificity and sensitivity of two candidate exosomal LncRNAs. Results: The APAP-induced hepatocellular injury model was successfully established for RNA-sequencing, leading to the identification of several differentially expressed exosomal LncRNAs. Eight upregulated exosomal DE-LncRNAs were selected for validation. Among them, NONRATT018001.2 (p < 0.05) and MSTRG.73954.4 (p < 0.05) exhibited a more than 2-fold increase in expression levels. In hepatocellular injury and intrahepatic cholestasis models, both NONRATT018001.2 and MSTRG.73954.4 showed earlier increases compared to serum biomarkers ALT and AST. However, no histological changes were observed until the final time point. In the fatty liver model, NONRATT018001.2 and MSTRG.73954.4 increased earlier than ALT and AST at 21 days. By the 7th day, minor steatosis was evident in liver tissue, while the expression levels of the two candidate exosomal LncRNAs exceeded 2 and 4 times, respectively. In the hepatic fibrosis model, NONRATT018001.2 and MSTRG.73954.4 showed increases at every time point. By the 49th day, hepatocellular necrosis and fibrosis were observed in the liver tissue, with NONRATT018001.2 showing an increase of more than 8 times. The specificity of the identified exosomal DE-LncRNAs was verified using a myocardial injury model and they showed no significant differences between the case and control groups. Conclusion: NONRATT018001.2 and MSTRG.73954.4 hold potential as biomarkers for distinguishing different types of organ injury induced by drugs, particularly enabling early prediction of liver injury. Further experiments, such as siRNA interference or gene knockout, are warranted to explore the underlying mechanisms of these LncRNAs.

Single-cell RNA Sequencing Reveals the Dynamics of Hepatic Non-Parenchymal Cells in Autoprotection Against Acetaminophen-Induced Hepatotoxicity

The Complex Roles of Neutrophils in APAP-induced Liver Injury.

Bifidobacterium Longum R0175 Protects Mice Against APAP-induced Liver Injury by Modulating the Nrf2 Pathway.

Single-cell RNA sequencing to reveal non-parenchymal cell heterogeneity and immune network of acetaminophen-induced liver injury in mice

Unraveling the effect of intra- and intercellular processes on acetaminophen-induced liver injury

Inhibiting Hepatocyte Uric Acid Synthesis and Reabsorption Ameliorates Acetaminophen-Induced Acute Liver Injury in Mice.

Targeting Innate Immune Responses to Attenuate Acetaminophen-Induced Hepatotoxicity

Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions

Therapeutic Role of Inducible Nitric Oxide Synthase Expressing Myeloid-Derived Suppressor Cells in Acetaminophen-Induced Murine Liver Failure

Comparison of Hepatic Transcriptome Profiling Between Acute Liver Injury and Acute Liver Failure Induced by Acetaminophen in Mice

Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans

The role of Neu1 in the protective effect of dipsacoside B on acetaminophen-induced liver injury

Mesenchymal stromal cells alleviate APAP-induced liver injury via extracellular vesicle-mediated regulation of the miR-186-5p/CXCL1 axis

The molecular mechanisms of acetaminophen-induced hepatotoxicity and its potential therapeutic targets

The role of exosomal lncRNAs in acetaminophen-induced induced liver injury in SD rats

Paeoniflorin protects hepatocytes from APAP-induced damage through launching autophagy via the MAPK/mTOR signaling pathway

Circulating Cell‐Free DNAs as a Biomarker and Therapeutic Target for Acetaminophen‐Induced Liver Injury

Apigenin Prevents Acetaminophen-Induced Liver Injury by Activating the SIRT1 Pathway

CD36 deficiency ameliorates drug-induced acute liver injury in mice

Hepatocyte‐Targeted Lipid Nanoparticle Delivery of HERC2 Plasmid Controls Drug‐Induced Hepatotoxicity by Limiting β‐Catenin‐Regulated CYP2E1 Expression

A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen